Absorption, distribution, metabolism, elimination (ADME)
Active pharmaceutical ingredient (API)
Adaptive trial
Ames test
Antibiotic, antibacterial and antimicrobial
Antimicrobial resistance (AMR)
Antimicrobial susceptibility testing (AST), resistance testing
Antiseptic
Bacterial efflux
Bacterial target
Bactericidal
Bacteriostatic
Breakpoint concentration, clinical
Candidate
Chemistry, manufacturing and controls (CMC)
Clinical Development
Cmax
Drug product, medicinal product
Epidemiological cut-off value (ECOFF)
ESKAPE
Extensively drug-resistant (XDR)
High-throughput screen (HTS)
Hit
Hit confirmation, hit validation
Hit expansion
Hit identification, hit discovery
Hit-to-lead (HTL), lead generation
Intracellular concentration
Investigational new drug (IND)
Lead compound
Lead optimization
Limited population pathway for antimicrobial and antifungal drugs (LPAD)
Lipophilicity
LogD
LogP
Marketing authorization application (MAA)
Maximum tolerated dose (MTD)
Mechanism of action (MoA)
Median effective dose (ED50)
Median lethal dose (LD50)
Medicinal chemistry
Minimum inhibitory concentration (MIC)
Multidrug-resistant (MDR)
New chemical entity (NCE), new molecular entity (NME)
New drug application (NDA)
Non-inferiority margin
Non-inferiority trial
Pandrug-resistant (PDR)
Pharmacodynamics (PD)
Pharmacokinetics (PK)
Pharmacokinetics-pharmacodynamics (PK/PD)
Pharmacovigilance
Phase 1, 2, 3, 4 trials
Placebo-controlled trial
Plasma concentration
Plasma protein binding
Preclinical development
Pro-drug
Qualified infectious disease product (QIDP)
Randomized clinical trial (RCT)